Stocks To Buy Now

Blog


2024 MoneyShow Toronto Conference to Feature 60+ Experts Helping 2,500+ Registrants Achieve Investment Success

MoneyShow’s annual Canadian investor and trader conference will run Sept. 13, 2024, through Sept. 14, 2024, at the Metro Toronto Convention Centre North. The theme of the 2024 event is “Outlook 2024-2025: Politics, Policy, & Profits” and it will feature more than 60 of North America’s top money experts.

They will be participating in two days of networking, discussions, presentations, and training workshops – as well as meet-and-greets, book signings, and a networking reception. More than 2,500 have already registered to attend the prestigious event.

The speakers gracing the event floor are eminent dignitaries with years of experience and proven financial strategies. They will conduct keynote presentations and workshops providing invaluable expertise to strengthen and safeguard one’s portfolio.

Points of discussion at this year’s event include:

  • Ways to increase portfolio returns against the backdrop of upcoming elections in the U.S. and Canada.
  • How to invest in gold, copper, oil, and other commodities.
  • Best stock and options trading strategies for maximum profit and income.
  • Tax and financial planning amidst key policy shifts.
  • Real estate opportunities given current and future market trends.
  • The most lucrative ETFs and stocks for investment.

MoneyShow has 43 years of experience in bringing traders and investors together and connecting them with top thought leaders in common forums. The firm hosts in-person conferences and online expos where financial experts offer sound advice that helps entrepreneurs, companies and investors maximize profits and minimize risks. Attendees at MoneyShow conferences stay up-to-date with the latest news, financial tools and data on investing opportunities and trading strategies.

To learn more, please visit https://ibn.fm/pbi4d

From Our Blog

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

April 9, 2026

Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its lead candidate, LB-100, at the nucleus of […]

Rotate your device 90° to view site.